BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//UC Berkeley//BEGIN//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:"The Resmetirom Story" Seminar with Rebecca Taub
X-WR-TIMEZONE:America/Los_Angeles
BEGIN:VEVENT
UID:the-resmetirom-story-seminar-with-rebecca-taub@begin.berkeley.edu
DTSTAMP:20261011T032204Z
SEQUENCE:0
DTSTART;TZID=America/Los_Angeles:20260414T140000
DTEND;TZID=America/Los_Angeles:20260414T153000
SUMMARY:"The Resmetirom Story" Seminar with Rebecca Taub
DESCRIPTION:The Journey to Development and Approval for the Treatment of MA
 SH with Liver Fibrosis: The Resmetirom Story: a Seminar by Dr. Rebecca Tau
 b\, Founder\, Director\, and Senior Medical and Scientific Advisor at Madr
 igal Pharmaceuticals. Steatotic liver disease (SLD)\, including MASH and a
 lcohol-related liver disease are among the top reasons for cirrhosis\, liv
 er failure\, hepatocellular carcinoma\, and liver transplant globally. Pat
 ient-centered collaboration across clinical-\, biomarker-\, data-\, and re
 gulatory science\, and between industry and academia\, has never been more
  important in SLD\, including MASH. Dr. Rebecca Taub will provide expert i
 nsight into the considerable\, critical\, challenges faced by MASH therape
 utic and biomarker developers based on her experience founding Madrigal Ph
 armaceuticals and guiding resmetirom (REZDIFFRA) through the Accelerated A
 pproval process.
LOCATION:Berkeley Way West
URL:https://forumresearch.formstack.com/forms/forum_april
END:VEVENT
END:VCALENDAR